ANI Pharmaceuticals vs VILYA
ANI Pharmaceuticals vs VILYA, compared side by side on 20 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: ANI Pharmaceuticals is on 49/100 and VILYA on 62/100.
Where each one leads
ANI Pharmaceuticals
- agent readiness: 31/100 against 26/100
- domain rating: 56/100 against 10/100
- headcount: 707 against 47
- funding raised: $671M against $121M
- LinkedIn following: 31,660 against 4,799
VILYA
- our overall score: 62/100 against 49/100
- headcount growth: +123.1% against +95.8%
At a glance
| Measure | ANI Pharmaceuticals | VILYA |
|---|---|---|
| What it is | Diversified biopharmaceutical company focused on rare diseases, generics, and established brands. | AI-powered platform for designing novel molecular structures for new medicines. |
| Category | Biotech, Pharmaceuticals, Rare Disease, Generics | BIO + LIFE SCIENCES, Biotech, Drug Discovery, Genomics |
| Sells toBusiness model | B2B | B2B |
| Offering | Software | hardware | services | marketplace | platform | Platform |
| Founded | 1996 | 2022 |
| Headquarters | Baudette, United States | San Francisco, United States |
| Status | Active | Active |
Size, funding and growth
| Measure | ANI Pharmaceuticals | VILYA |
|---|---|---|
| Employees | 707 | 47 |
| Headcount growthLast 12 months | +95.8% | +123.1% |
| Total funding | $671M | $121M |
| Latest round | Acquisition | Series A |
| LinkedIn followers | 31,660 | 4,799 |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | ANI Pharmaceuticals | VILYA |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 49/100 | 62/100 |
| Traction | 60/100 | 57/100 |
| Team | 10/100 | 70/100 |
| Search visibility | 23/100 | 34/100 |
| Quality | 58/100 | 68/100 |
| Agent readinessHow well an AI agent can read and act on the site | F (31/100) | F (26/100) |
| Domain ratingLink authority, 0-100 | 56/100 | 10/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | ANI Pharmaceuticals | VILYA |
|---|---|---|
| Hosting | Self Managed | Not detected |
| CDN | Not detected | Cloudflare |
| Frameworks | Jquery, Bootstrap | Svelte, Astro, Tailwind CSS |
| Analytics | Google Analytics 4 | Not detected |
ANI Pharmaceuticals vs VILYA: common questions
Which is better, ANI Pharmaceuticals or VILYA?
On our 0-100 score VILYA rates higher (62/100 against 49/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 20 data points above: read the rows that match what you are buying for.
How do ANI Pharmaceuticals and VILYA compare on the numbers?
ANI Pharmaceuticals leads on agent readiness (31/100 against 26/100), domain rating (56/100 against 10/100), headcount (707 against 47), funding raised ($671M against $121M), LinkedIn following (31,660 against 4,799). VILYA leads on our overall score (62/100 against 49/100), headcount growth (+123.1% against +95.8%).
Read the full ANI Pharmaceuticals review and pricing or the VILYA review and pricing. You can also browse other ANI Pharmaceuticals alternatives we track.